Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsRusfertide (Mimrylo) just received FDA approval for polycythemia vera — and it's reshaping a field long dominated by repeat blood draws. The first-in-class hepcidin mimetic lets patients self-inject weekly to keep hematocrit in check, significantly reducing phlebotomy dependence. NCCN has already granted it Category 1 status across both low- and high-risk disease, making it the only therapy to hold that distinction.
Polycythemia vera (PV) patients have long been caught in a frustrating cycle: too many red blood cells, repeated phlebotomies to drain them, worsening iron deficiency, and then even more red blood cell production. Rusfertide (Mimrylo), FDA-approved in August 2026, breaks that loop. As a first-in-class hepcidin mimetic, it raises hepcidin levels to restrict iron delivery to the bone marrow, curbing red blood cell overproduction — and patients can self-inject it once weekly at home.
The approval is based on the phase 3 VERIFY trial, which enrolled phlebotomy-dependent PV patients on various standard-of-care backbones. Rusfertide significantly outperformed placebo on the primary endpoint, and NCCN has since awarded it a Category 1 recommendation across both low- and high-risk PV — a first for any single agent in this setting. Beyond hematocrit control, patients also reported meaningful improvements in fatigue and quality of life.
By the Numbers:
Why it matters: For a disease patients live with for decades, rusfertide offers something genuinely new — consistent hematocrit control, reduced clinic burden, and real symptom relief. It's the first therapy that directly addresses what patients say matters most: getting their lives back.
